Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.60 |
| ▸ | CA1 | P00915 | 1/20 | 0.60 |
| ▸ | CA2 | P00918 | 1/20 | 0.60 |
| ▸ | CA9 | Q16790 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 4/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | THRB | P10828 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21621323 | 0.92 | MTNR1A (0.55) | CA12CA1CA2CA9SMN1; SMN2 | |
| SCHEMBL8099685 | 0.90 | CA1 (0.73) | CA12CA1CA2CA9KMT2A | |
| SCHEMBL10310254 | 0.86 | KMT2A (0.59) | CA12CA1CA2CA9KMT2A | |
| SCHEMBL6987265 | 0.84 | KMT2A (0.57) | CA12CA1CA2CA9KMT2A | |
| SCHEMBL9269689 | 0.83 | KMT2A (0.59) | KMT2ALMNAMAPTALDH1A1HPGD | |
| SCHEMBL31467954 | 0.83 | MTNR1A (0.62) | CA12CA1CA2CA9KMT2A | |
| SCHEMBL6478319 | 0.83 | KMT2A (0.62) | KMT2ALMNAMAPTTP53THRB | |
| SCHEMBL21621330 | 0.82 | KMT2A (0.58) | CA12CA1CA2CA9KMT2A | |
| SCHEMBL10310313 | 0.82 | KMT2A (0.62) | CA12CA1CA2CA9KMT2A | |
| SCHEMBL11446232 | 0.81 | KMT2A (0.67) | KMT2ALMNAALDH1A1SMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240217974-A1 | ISOQUINOLONE COMPOUND AND USE THEREOF | JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) | 2024-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240217974-A1 | ISOQUINOLONE COMPOUND AND USE THEREOF | CYP4A11, CYP11B2, NQO1 | CA12 4154/4885CA1 3724/4885CA2 2727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.